NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order
Globe Newswire•05/10/2026•09:17 ET
0
Key Highlights
- ➤Q4 product revenue $3.8 million, up 38.4% year over year
- ➤Full-year product revenue $10.5 million, up 15.6%, tops guidance range
- ➤$4.5 million purchase order secured, largest in NeuroOne’s history
- ➤$5.4 million open purchase orders support shipments through fiscal Q1 2027
Expert Statements
Dave Rosa, Chief Executive Officer of NeuroOne
“Momentum continues to build across our business.”
Dave Rosa, Chief Executive Officer of NeuroOne
“We are happy to report that product orders increased 24.2% in fiscal 2026 compared to fiscal 2025. We enter fiscal 2027 from a position of strength supported by $5.4 million in open purchase orders and we are also very well positioned with additional growth drivers including the commercialization of our trigeminal neuralgia system, international market expansion, and the advancement of our drug delivery platform.”
Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range
EDEN PRAIRIE, Minn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced preliminary, unaudited product revenue for its fourth fiscal quarter and full fiscal year ended September 30, 2026, and provided an update on recent product orders.
Get started
Create a free account to read the full story.